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Flk-1Ras proteins are small GTPases that regulate cellular growth and differentiation. Components of the Ras
signaling pathway have been shown to be important during embryonic vasculogenesis and angiogenesis.
Here, we report that Rasip1, which encodes a novel Ras-interacting protein, is strongly expressed in vascular
endothelial cells throughout development, in both mouse and frog. Similar to the well-characterized vascular
markers VEGFR2 and PECAM, Rasip1 is speciﬁcally expressed in angioblasts prior to vessel formation, in the
initial embryonic vascular plexus, in the growing blood vessels during angiogenesis and in the endothelium
of mature blood vessels into the postnatal period. Rasip1 expression is undetectable in VEGFR2 null embryos,
which lack endothelial cells, suggesting that Rasip1 is endothelial speciﬁc. siRNA-mediated reduction of
Rasip1 severely impairs angiogenesis and motility in endothelial cell cultures, and morpholino knockdown
experiments in frog embryos demonstrate that Rasip1 is required for embryonic vessel formation in vivo.
Together, these data identify Rasip1 as a novel endothelial factor that plays an essential role in vascular
development.
© 2009 Elsevier Inc. All rights reserved.Introduction
The cardiovascular system, which includes the entire network of
blood vessels and the heart, is the ﬁrst functional organ system to
form in the embryo. Defects in the structure and/or function of the
cardiovascular system inevitably lead to early embryonic lethality
(Cleaver and Krieg, 1999). Initially, the vasculature emerges from
aggregation of angioblasts. Angioblasts are endothelial precursors that
arise from mesodermal cells that differentiate either within blood
islands, structures composed of hematopoietic cells (blood cell
precursors) surrounded by a mantle of angioblasts, or within
embryonic tissues as scattered cells. Vessels subsequently form via
vasculogenesis, or the coalescence of individual angioblasts “in situ”
to form primitive vascular ‘cords’, which then undergo tubulogenesis
(Risau and Flamme, 1995). The ﬁrst vessels consist of a relatively
simple and homogeneous endothelial cell (EC) network of vessels,
often termed a ‘plexus’. Subsequently, the complexity of the
vasculature increases dramatically as new vessels sprout and extend
from pre-existing vessels, via a process called angiogenesis (Risau,
1997). Angiogenic remodeling of blood vessels then transforms the(O. Cleaver).
l rights reserved.initially simple, net-like, primary plexus, into a complex hierarchical
network of large and small vessels, which includes specialized ECs,
such as arteries and veins. As these vessels mature and stabilize, they
become ensheathed by smooth muscle cells and pericytes. However,
they continue to grow coordinately with organs and tissues, providing
the tissues they perfuse with the nutrients and oxygen required for
viability.
Most of the molecular mechanisms responsible for blood vessel
formation are not yet well understood. For decades, much attention
was given to the role of vascular endothelial growth factor (VEGF) and
its inﬂuence on EC migration and proliferation (Ferrara et al., 2003;
Yancopoulos et al., 2000). Recently, however, discovery of a host of
endothelial ‘guidance’ cues, which either attract or repel ECs and
shape individual blood vessels, has broadened our understanding of
how cell–cell signaling inﬂuences the morphogenesis of individual
vessels and the vascular network as a whole. These signaling
molecules include the Eph/ephrins (Kuijper et al., 2007), bone
morphogenetic proteins (BMPs) (Lebrin et al., 2005; Moser and
Patterson, 2005; Park et al., 2006), transforming growth factors
(TGFβs) (Lebrin et al., 2005), Notch and Notch ligands (Roca and
Adams, 2007) and many others. In addition, a number of cell-
autonomous factors have also recently been shown to be critical for
proper EC behavior and blood vessel formation. Many of these factors,
such as small GTPases Ras, Rho, Rac, Cdc42, Pak and their many
effectors/modulators (Fryer and Field, 2005; Garnaas et al., 2008;
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2005; Tan et al., 2008) are already known to drive basic cell processes
such as cell migration, cell proliferation and establishment of cell
polarity. Despite recent advances, the molecular mechanisms under-
lying much of blood vessel formation in vivo remain unclear, and
elucidation of both extracellular signaling events and cell-autono-
mous regulatory signaling cascades will advance our understanding of
vascular speciﬁcation and patterning, in both normal and pathological
conditions (Coultas et al., 2005).
Many Ras family members and their regulators have been
implicated in vascular development (Gitler et al., 2003; Henkemeyer
et al., 1995; Tan et al., 2008), including EC migration (Sosnowski
et al., 1993; Tan et al., 2008), capillary tube assembly (Connolly et al.,
2002), angiogenesis (Aitsebaomo et al., 2004; Fryer and Field, 2005;
Kranenburg et al., 2004; Merajver and Usmani, 2005), blood vessel
homeostasis (Komatsu and Ruoslahti, 2005) and vascular perme-
ability (Serban et al., 2008). Ras molecules are small GTPases widely
shown to function as molecular switches coordinating multiple
cellular behaviors like growth, proliferation, migration and differ-
entiation. Ras GTPases cycle between the GTP-bound (active) and
GDP-bound (inactive) states, under the inﬂuence of GAPs (GTPase
Activating Proteins), and GEFs (GTPase Exchange Factors). Ras family
proteins have been shown to activate signaling cascades down-
stream of VEGF (Cross et al., 2003; Kranenburg et al., 2004; Roberts
et al., 2004). VEGF stimulation of ECs increases the amount of
activated Ras, while dominant negative Ras constructs inhibit VEGF-
induced endothelial proliferation, migration and assembly (Mea-
dows et al., 2001). However, although the Ras pathway proteins have
been implicated in vascular development, their exact role is not well
understood.
Recently, Mitin et al. (2004) reported the identiﬁcation of a novel
Ras-interacting protein, Rasip1/Rain, which displays the character-
istics of an endomembrane Ras effector. Their experiments showed
that Rasip1 possesses a Ras-associating domain (RA), homologous to
the RA domains of other Ras effectors, and that Rasip1 preferentially
binds to the GTP-loaded form of Ras, both in vitro and in vivo. In
addition, they demonstrated that transfected Rasip1 localizes to a
perinuclear, juxta-Golgi region in intact COS cells and is recruited to
the Golgi by active Ras. Its enrichment in adult lung and high
expression in transformed EC lines suggested the possibility that
Rasip1 is expressed by ECs (Mitin et al., 2006).
In an effort to discover unknown regulators of blood vessel
development, we performed a microarray screen that transcription-
ally proﬁled embryonic aortal ECs (Xu and Cleaver, unpublished).
Among numerous EC-enriched transcripts, we identiﬁed Rasip1.
Here, we show that expression of Rasip1 is strikingly restricted to
the endothelium of the developing vasculature, in both frog and
mouse, and we demonstrate that Rasip1 is essential for proper
endothelial cell angiogenic assembly and migration, both in vivo and
in vitro. We propose that Rasip1 plays important roles during
vasculogenesis and angiogenesis, possibly regulating the function of
Ras proteins in ECs.
Materials and methods
Isolation of Rasip1 sequence
A pYX plasmid containing mouse Rasip1 cDNA piece (1047–
3170 bp, spanning exons 4 through 7) was obtained from Open-
Biosystems (BC072584). For making longer in situ probes, the full-
length coding region (2886 bp) of Rasip1 was ampliﬁed from E8.5
mouse cDNA by RT-PCR, using 5′ primer ATGCTATCTGGTGAACGAAAG
and 3′ primer TCAAGGTGTCGAAGCCACCG. PCR fragments were
inserted into pGEM-T-Easy Vector (Promega) by TA cloning. Xenopus
tropicalis Rasip1 partial coding region sequence (1151 bp, exon 2–exon
7) was cloned by RT-PCR using primers: 5′ primer ATTAAGGGAAAGA-GAAGAAAGCATCT and 3′ primer GCATACAGTGTCTTGGTCAGATAATA-
TAC. The ampliﬁed fragment was subcloned into pGEM-T-Easy Vector
(Promega) by TA cloning.
Embryos and histology
CD1 embryos were collected from pregnant females (E7.5 through
E15.5) after dissection in ice-cold PBS buffer and ﬁxed in 4%
paraformaldehyde in PBS solution overnight at 4 °C with gentle
rocking. The amnion was removed during dissection for better probe
penetration. Embryos were washed three times in PBS for 5 min, and
dehydrated using a series of ethanol washes. Embryos were then
stored in 75% ethanol at −20 °C. Postnatal tissue was collected and
ﬁxed in a similar manner.
For wax sectioning of embryos following in situ hybridization, the
embryos were ﬁxed and dehydrated as described above. Embryos
were rinsed twice in 100% ethanol for 5 min, twice in xylene at room
temperature (RT) for 10min, then amixture of 1:1 paraplast:xylene at
60 °C for 10 min, then a series of 100% paraplast at 60 °C (McCormick
Scientiﬁc). The embryos were then embedded and sectioned with a
Biocut 2030 microtome. For examination, the sections were placed on
glass slides, deparafﬁnized in xylene twice for 5 min each and
mounted on SuperfrostPlus glass slides (Fisher) using Permount
(Fisher).
Digoxigenin-labeled RNA probes
Rasip1 (in pYX plasmid) was linearized using EcoRI and an
antisense Digoxigenin(Dig)UTP-labeled RNA probe was synthesized
using T3 polymerase. VEGFR2 coding region was ampliﬁed from
mouse E8.5 cDNA with primers 5′ primer GACGGAGAAGGAGTCTGTGC
and 3′ primer GGGACAGGACCACTTCCAT and cloned into pGEM-T-Easy
vector. This VEGFR2 clone was linearized using SpeI and an antisense
Dig-labeled RNA probe was synthesized using T7 polymerase. A
PECAM clone, containing 950 bp of 3′UTR (and kindly provided by D.
Melton), was linearized using XhoI and an antisense Dig-labeled RNA
probe was synthesized using T3 polymerase. Probe synthesis was
carried out at 37 °C for 2 h: 1 μg linearized plasmid, 2.0 μl DIG-RNA
labeling mix (Roche), 2.0 μl 10× transcription buffer (Roche), 1.5 μl
Placental ribonuclease inhibitor (Promega), 1.0 μl T3/T7 RNA poly-
merase (Roche), RNase free water to a ﬁnal volume of 20 μl. DNA
template was removed using 2 μl RQ1 DNase I (Promega), at 37 °C for
15 min. The probes were then puriﬁed with Micro Bio-spin columns
(Bio-RAD). 10× hybridization stock solution was prepared at a
concentration of 10 μg/ml in ‘prehyb’ solution: 50% Formamide
(Fisher), 5× SSC (pH 4.5), 50 μg/ml Ribonucleic acid from Torula
yeast, Type VI (Sigma), 1% SDS, 50 μg/ml Heparin (Sigma). Stock
solution is stored at −80 °C.
Whole mount in situ hybridization
Whole mount in situ hybridization in mouse embryos was
carried out using a protocol adapted from D. Wilkinson's method
(Wilkinson, 1999). Brieﬂy, embryos stored in 75% ethanol at −20 °C
were rehydrated in stepwise fashion to PBST. Then, the embryos
were treated with 10 μg/ml proteinase K (time treated varied with
age of tissue; 2 min–30 min), ﬁxed in a 0.2% gluteraldehyde/4%
paraformaldehyde (PFA) solution, and pre-hybridized at 65 °C for
1 h. The samples were transferred into hybridization mix, containing
1 μg/ml Dig-labeled probes described above. The in situ hybridiza-
tion post-hybridization washes and antibody incubation were
carried out using a Biolane HTI automated incubation liquid handler
(Holle & Huttner). Color development was carried out using BM
purple solution (Roche). Frog in situ hybridization was carried out
using a similar standard in situ hybridization protocol (Costa et al.,
2003).
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Parafﬁn sections (on glass slides) were washed 3×3 min in PBS,
followed by a 10 min treatment with 15 μg/ml proteinase K. Sections
were then rinsed in PBS, ﬁxed in 4% PFA for 5 min, and incubated for
10min in acetylation solution: mix of 2.66 ml Triethanolamine, 350 μg
HCl, 750 μg acetic anhydride and 200 ml water. Prehybridization was
carried out in plastic slide mailers (Fisher) containing hybridization
buffer at RT for 1 h. Slides were then transferred to a humidiﬁed
chamber (humidiﬁed with 50% formamide/5×SSC) for probe hybri-
dization (probe at 1 μg/ml) with 100 μl probe/slide (covered with
glass coverslips) at 68 °C overnight.
Slides were washed post-hybridization in 2× SSC at 72 °C just
long enough to allow coverslips to separate. Then slides were rinsed
in 0.2× SSC at 72 °C and RT for 1×1 min, respectively, then MBST
buffer at RT (100 mM Maleic acid, 150 mM NaCl, pH 7.5, 0.1%
Tween20). Slides were incubated in blocking solution (2% blocking
reagent (Roche) and 5% heat-inactivated sheep serum in MBST) for
1 h at RT. Anti-Dig alkaline phosphatase conjugated antibody was
applied on slides in a chamber humidiﬁed with MBST (250 μl of
1/4000 anti-Dig antibody (Roche)), covered with paraﬁlm and
incubated at 4 °C overnight. Slides were washed for 3×30 min in
MBST after antibody incubation, and treated in NTMT (100 mM
NaCl, 100 mM Tris, pH 9.5, 50 mM MgCl2, 0.1% Tween20) for
3×5 min. Color reaction was carried out using BM purple as
described above. For microscopic examination, slides were sealed
and coverslipped using Permount (Fisher).
VEGFR2 null embryo generation and β-galactosidase reaction
VEGFR2 null embryos were generated by mating Flk1(VEGFR2)-
lacZ heterozygous males and females (kindly provided by Drs. Janet
Rossant and Eli Keshet). Embryos were dissected manually in ice-
cold PBS. Embryos lacking blood vessels were identiﬁed visually, by
the absence of yolk sac blood vessels, and genotypes (of either
embryos or adults) were conﬁrmed by PCR, using primers to lacZ; 5′
primer GGTGGCGCTGGATGGTAAGC, 3′primer CGCCATTTGACCAC-
TACC, which yield a 630 bp PCR fragment. For the β-galactosidase
reaction Flk-1(VEGFR2)+/− and Flk-1(VEGFR2)−/− embryos (or
isolated organs) were ﬁxed in 5 mM EGTA (pH 8.0), 0.2%
gluteraldehyde, 2 mM MgCl2 and PBS solution for 15 min on ice.
After ﬁxation, embryos were rinsed 3 times for 5 min in PBS. 50 mM
Potassium Ferrocyanide (K4Fe(CN)6·3H2O) and Potassium Ferricya-
nide (K3Fe(CN)6) solutions, stored at RT in dark, were used to make
lacZ staining solution: 20 mM K4Fe(CN)6·3H2O, 20 mM K3Fe(CN)6,
2 mM MgCl2, 0.02% NP-40, add water or 1×PBS to 500 μl. Staining
solution was warmed to 37 °C before adding X-Gal (Growcells) to
avoid X-Gal precipitation. 4 μl of 100 mg/ml X-Gal stock (in
dimethyl formamide) was then added to the lacZ staining solution.
Embryos were placed in staining solution and color reaction was
allowed to develop at 37 °C overnight. When staining was evaluated
to be optimal, embryos were washed with PBS 3 times for 5 min
each, post-ﬁxed in 4%PFA overnight, and transferred to 80% glycerol
for viewing.
siRNA transfection and endothelial cell assays
siRNAs were ordered from IDT-DNA as the TriFECTa Kit.
Sequences: siHPRT: 5′ primer AAUUUCAAAUCCAACAAAGUCUGGCUU.
siRasip1: 5′ primer CCAUCUCUAGCACUUUCUCCUGUACAA. The trans-
fection was carried out in the 24-well plate format. For each well,
1.25 μl of 20 μM dicer substrate siRNA was diluted in 50 μl of Opti-
MEM I Reduced Serum Medium (Invitrogen). 1 μl of Lipofectamine
2000 (Invitrogen) transfection reagent was diluted in another 50 μl
of Opti-MEM I Reduced Serum Medium. After 5 min incubation at
RT, the diluted siRNA and the transfection reagent were combinedtogether, and incubated for 20 min at RT. MS1 cells (ATCC) were
plated on a 24-well plate with a density of 5×104 cells/well in
400 μl DMEM containing 10% FBS and without penicillin/strepto-
mycin. The pre-mixed 100 μl transfection complexes were then
added drop-wise on top of the cells. After gentle mixing by rocking
the plate back and forth, the cells were incubated at 37 °C in a 5%
CO2 incubator prior to following assays.
For analyzing transcription of the targeted genes in these assays,
cells were trypsinized 72 h post-transfection, and the total RNAs were
isolated using an RNeasy Mini Kit (Qiagen). First strand cDNAs were
made using M-MLV Reverse Transcriptase (Promega) based on
manufacturer standard protocols. Rasip1 primers: 5′ primer GGAG-
CAGCTTACGGACTGAC, 3′ primer CCATCGTCTACCAACCCAAC. HPRT
primers: idtDNA HPRT primer set. β-Actin primers: 5′ primer
GTTGGTTGGAGCAAACATCC, 3′ primer AGGGAGACCAAAGCCTTCAT.
The transcripts were ampliﬁed in a 30-cycle polymerase chain
reaction.
‘Tube-formation assays’were carried out in a 96-well plate. 50 μl of
Matrigel (BD Matrigel 354234) was thawed on ice and plated on the
bottom of each well. ECs cultured in one well of a 24-well plate (90%
conﬂuency) were trypsinized, plated in one Matrigel coated well of a
96-well plate and cultured at 37 °C. When using wildtype cells, the
angiogenic aggregation of ECs (or ‘tubes’) starts to occur within a few
hours. For better viewing, cells were stainedwith 1 μM ﬂuorescent dye
Calcein-AM (Cell Biolabs) before microscopic examination. Quantiﬁ-
cation of angiogenic branchpoints was accomplished by counting
observable branchpoints within 8 representative areas within each
plated well. ‘Branchpoints’ are deﬁned as the intersection point of two
linear, vessel-like vascular structures, as previously deﬁned by others
(Hellstrom et al., 2007).
‘Wound-healing’ assays were carried out 72 h post-transfection.
Brieﬂy, the cell monolayer is scratched using a sterile P200 pipette
tip to create a ‘cell-free’ area (the wound, width of ∼600 μm). The
cells were then immediately washed once with DPBS to remove
detached cells from the wound area. Cells on the scratched plate are
then allowed to recover and migrate into the ‘cell-free’ area. Images
were acquired immediately after scratching and rinsing, and also
after an overnight incubation at 37 °C for comparison of wound
width. Distance migrated was calculated as half of the total change
in width.
Cell proliferation was analyzed in cultured ECs by Ki67 staining.
72 h post-transfection of siRasip1, cells were washed 3 times in PBS,
and then ﬁxed in 4% PFA for 10 min at RT. For better antibody
penetration, the cells were incubated in PBSN (0.1% NP-40 in PBS) for
15 min with gentle rocking. Cells were then incubated in blocking
solution (5% donkey serum (sigma), 1% BSA (Fisher) in PBSN) for
30 min at RT. Primary rabbit anti-Ki67 antibody (Vector laboratories)
and secondary antibodies (Alexa488 conjugated anti-rabbit, Invitro-
gen) were applied at 1:500 dilution in blocking solution at RT for 1 h.
Cells were rinsed 3×5 min in PBSN following each antibody
incubation. Cells were then mounted in Vectashield mounting
media (Vector laboratories) and examined using a Zeiss Axiovert
ﬂuorescent microscope.
Morpholino (MO) knockdown of Xenopus Rasip1
X. tropicalis embryos were injected with 16 ng Rasip1-MO (Gene-
tools) into 1 cell at the 2-cell stage for assessment of vascular defects
using in situ hybridization, or into both cells for assessment of
transcript knockdown by RT-PCR. Embryos were allowed to develop to
stage 32, then ﬁxed in preparation for in situ hybridization.
Morpholino-injected embryos were ﬁxed in MEMFA (0.1 M MOPS
pH 7.4, 2 mM EGTA, 1 mMMgCl2, 4% PFA), transferred to 100% ethanol
and stored at −20 °C. For evaluation of transcript knockdown
efﬁciency, embryos were allowed to develop to either stage 25/26
or 29/30 and frozen directly on dry ice for RT-PCR.
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Identiﬁcation of Rasip1 expression in murine endothelial cells
To identify sequences enriched in the embryonic dorsal aortae, we
carried out Affymetrix microarray screening of aortal ECs from E8.25
mouse embryos (Xu and Cleaver, unpublished). dChip (Li and Wong,
2001) and Genespring software analysis was used to compare array
data (to non-vascular array sets) and extract endothelial-enriched
sequences.We initially identiﬁed Rasip1 as an EST (AI853551) showing
50-fold enrichment in ECs over other tissues. A longer clone was
acquired commercially (OpenBiosystems), allowing production of
Dig-labeled antisense probes encompassing the region from exon 4
through exon 12 (∼2000 bp) of the Rasip1 transcript. The Rasip1Fig. 1. Expression of Rasip1 in vascular endothelium during early embryogenesis. In situ hybr
(A–F) Whole mount in situ hybridization showing whole stained embryos. Note expression
intersomitic vessels (ISVs) (red arrowheads). (G–I) Transverse sections of in situ hybridizati
sac vessels (thick arrow), and (I) heart endocardium. (J–L) Comparison of Rasip1 expressio
similarity of expression, especially in the ISVs (red arrowheads) and trunk vessels. Note differ
arrows). al, allantois; e, endocardium; en, endoderm; m, myocardium. The scale bars repregenomic structure has been previously described (Mitin et al., 2004),
however no developmental expression or function has been reported.
Rasip1 is expressed in vascular endothelium during vascular plexus
formation (E7.5–E10.0)
Using in situ hybridization, we characterized embryonic expres-
sion of Rasip1 in mouse embryos and found it to be principally
expressed in vascular endothelium. At E7.0 Rasip1 is initially detected
in the parietal yolk sac, in a punctate ring of cells (data not shown).
Soon thereafter, at E7.5, expression expands to scattered cells of the
extraembryonic yolk sac blood islands (Fig. 1A). At E8.0, individual
cells expressing Rasip1 within the extraembryonic mesoderm can be
observed at increasingly ventrolateral locations, in regions previouslyidization showing expression of Rasip1 in embryonic vessels at stages indicated (A–I, K).
in both scattered angioblasts (thin arrows), forming dorsal aortae (black arrowheads),
ons showing endothelial-speciﬁc expression of Rasip1 in panel G dorsal aortae, (H) yolk
n with that of the vascular markers VEGFR2 and PECAM, in E9.5 embryos. Note overall
ence in intensity of vascular staining in distinct regions, such as the cephalic vessels (red
sent 200 μm in all panels except J–L, where they represent 50 μm.
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Yoder, 2005). The punctate appearance of Rasip1 expression in
extraembryonic tissues at this stage suggests that these cells are
angioblasts (Fig. 1B), as it closely resembles that of vascular
endothelial growth factor receptor 2, VEGFR2 (or Flk1/KDR), and
Tal1 both established markers for early angioblasts (Drake and
Fleming, 2000). At E8.25–E8.5, Rasip1 is strongly expressed through-
out the embryonic and extraembryonic endothelium in a pattern
recognizable as the primary vascular plexus, including the endocar-
dium, the forming dorsal aortae and the primordia of the cardinal
veins (Figs. 1C,D). During these stages, vasculogenesis of the principal
embryonic blood vessels is occurring and major vessels are taking
shape (i.e. parallel dorsal aortae in Fig. 1D) (Walls et al., 2008).
As embryogenesis continues, Rasip1 expression continues to be
expressed in developing blood vessels. After embryonic turning, at
E8.75, expression is evident in all large and small blood vessels,
including the sprouting intersomitic/intersegmental vessels (ISVs)
(Fig. 1E). Expression of Rasip1within ISVs of later embryos (Figs. 1E, F,
K) suggests a role not only during vasculogenesis, but also during
extension of vascular sprouts, or angiogenesis. Transverse sections
through E8.5 embryonic tissues reveal that expression is restricted to
the endothelium in all tissues examined, including the dorsal aortae
(Fig. 1G) and yolk sac vessels (Fig. 1H). In addition, Rasip1 is expressed
within the endothelium of the endocardium, but not in myocardium
(Fig. 1I).
We compared expression of Rasip1 with that of other known
vascular markers, such as VEGFR2 and PECAM (Figs. 1J–L and Suppl.
Fig. 1), and found that Rasip1 outlined almost identical vascular
structures in the embryo. For instance, expression of all three markers
was observed in aortae, ISVs, endocardium and vessels of the lateral
plate and headmesoderm. Of note, different vascular beds appeared to
express these three vascular markers with varying intensity. ForFig. 2. Vascular expression of Rasip1 in embryonic organs and tissues. Flk1(VEGFR2)-lacZ wh
markers in isolated embryonic tissues, at stages indicated. A, D columns) Whole moun
hybridization of Rasip1 (B, E columns) and PECAM (C, F columns). A–F) Hearts. A′–F′) Lungs.
as marked by VEGFR2 and PECAM expression (black arrows). Expression of all three vascular m
C) and of the coronary vasculature (arrows, D–F). Expression of all threemarkers is evident in
ECs of the most distal tips of the buds at E10.5 (thick red arrows), while both VEGFR2 and Ra
vessels at E10.5, where VEGFR2 is robustly expressed in the most mediolateral/distal vessels
arrows, A″–C″). Rasip1 is expressed in the vessels of the developing limb buds, including th
trachea; te, telencephalon; v, ventricle. The scale bars represent 100 μm in A–F′ and 250 μminstance, the head plexus of E9.5 embryos expressed VEGFR2 more
robustly, while Rasip1 was more strongly expressed than either
VEGFR2 or PECAM in the ISVs and endocardium (Figs. 1J–L and Suppl.
Fig. 1). These differences reveal surprising endothelial heterogeneity
at early stages of vascular development. Nonetheless, overall expres-
sion analysis suggests that Rasip1 is primarily restricted to vascular
endothelium.
Rasip1 during late embryogenesis (E10.5–birth)
Analysis of Rasip1 transcripts later during development reveals
their expression in established vessels. Expression could indeed be
detected in the blood vessels of various organs throughout midgesta-
tion stages (Fig. 2 and Suppl. Fig. 2). Speciﬁcally, we found Rasip1
strongly expressed in the vessels of all embryonic organs and tissues
examined, including heart (Figs. 2B, E, Suppl. Figs. 2B, C, E, H), lung
(Figs. 2B′, E′, Suppl. Figs. 2C, D, G), head (Fig. 2B″), limb bud (Fig. 2E″),
pancreas, spleen and stomach (Suppl. Figs. 2J–L). When compared to
the expression of VEGFR2 (Fig. 2 columns A, D) and PECAM (Fig. 2
columns C, F), we found that Rasip1 generally marked identical
vascular beds, with only slight variations in expression intensity (Fig.
2 columns B, E). Expression of Rasip1 in later embryonic vessels, after
their formation via either vasculogenesis or angiogenesis, implies that
it has a maintenance function in mature vessels. Indeed, Rasip1
continued to be expressed in the endothelium of vessels into postnatal
stages (Suppl. Fig. 3) and was detected in adult organs, particularly in
the highly vascularized lung (Mitin et al., 2004).
Rasip1 expression is absent in vascularless embryos
To deﬁnitively test whether Rasip1 is restricted to vascular
endothelium, we assessed its expression in VEGFR2 mutant embryosole mount β-galactosidase staining and whole mount in situ hybridization of vascular
t β-galactosidase staining using Flk1(VEGFR2)-lacZ embryos. Whole mount in situ
A″–C″) Heads. D″–F″) Limb buds. Note similarity of expression of Rasip1 in most vessels,
arkers can be observed in the endocardium of the ventricle trabeculae in the heart (A–
the proximal ECs of the early lung buds (A′–C′), although PECAM is not expressed in the
sip1 are observed in this population. This heterogeneity is also observed in the cephalic
of the mesencephalon, while Rasip1 and PECAM are expressed at lower levels (thin red
e interdigit vessels (white arrows, D″–F″). a, atria; b, bronchus; br, branchial arches; t,
in A″–F″.
Fig. 3. Expression of Rasip1 is restricted to VEGFR2-dependent endothelium. Whole mount in situ hybridization and β-galactosidase staining to detect expression of Rasip1 and
VEGFR2. (A, B, A′, B′) Comparison of Flk1(VEGFR2)-lacZ staining and Rasip1 expression. Note overall similarity of expression. Rasip1 expression closely resembles Flk1(VEGFR2)-
lacZ expression at both E8.5 (A, B) and E9.0 (A′, B′). (C, C′) VEGFR2−/− null embryos, lacking all endothelium. Embryos in C–C″ have been stained by in situ hybridization for Rasip1
expression and allowed to develop same length of time as wildtype embryos in B–B″. Note complete lack of Rasip1 expression in these mutants. (A″–C″) Sections through embryos in
A′–C′ showing presence of aortae and perineural vascular plexus inwildtype embryos, while these vascular structures are missing in VEGFR2−/− embryos. al, allantois; g, gut tube;
h, heart; hd, head; da or black arrowheads, dorsal aortae; n, neural tube; ys, yolk sac. The scale bars represent 200 μm (A′–C′) and 50 μm (A–C, A″–C″).
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compared Rasip1 expression (Fig. 3 column B) to that of Flk1
(VEGFR2)-lacZ (Fig. 3 column A) in VEGFR2+/− heterozygous mice,
which display no detectable abnormalities, and found both outlined
the developing vasculature as expected. However VEGFR2−/−
homozygotes, which lack all blood vessels, exhibited no trace of Ra-
sip1 expression by in situ hybridization (Fig. 3 column C). Rasip1 and
VEGFR2 are expressed in similar vascular domains in VEGFR2
heterozygotes, from E8.25 to E9.0, while in VEGFR2 null embryos we
observed no Rasip1 expression in any embryonic region. These
ﬁndings suggest that Rasip1 is expressed exclusively in VEGFR2-
dependent cell types. Given that VEGFR2 is primarily expressed in and
required for ECs (Shalaby et al., 1995; Yamaguchi et al., 1993), it is
likely that Rasip1 is also expressed exclusively in those cell types, but
not in other non-vascular mesodermal or mesenchymal cell popula-
tions. We propose that Rasip1 is a novel and largely speciﬁc marker of
embryonic blood vessels throughout development.
Rasip1 is required for angiogenesis in cultured ECs
To identify the potential role of Rasip1 in ECs, we used an in vitro
siRNA approach to knockdown endogenous Rasip1 expression in
cultured mouse ECs (Fig. 4A). To identify endothelial cell lines that
expressed Rasip1, we screened a number of lines using RT-PCR. We
found that MS1, bEnd.3 and SVEC endothelial cell lines (ATCC) all
expressed Rasip1 to varying degrees, while non-vascular lines such asHEK293, Balb3 and NIH3T3 did not (data not shown), supporting the
notion that Rasip1 is a marker of endothelium. MS1 cells expressed
the highest levels of both Rasip1 and VEGFR2, therefore we chose this
line for subsequent assays. When siRNAs targeting Rasip1 were
transfected into MS1 cells, the cells displayed an abnormal ‘elongated’
morphology, compared to untreated (wildtype, WT) or positive
(siHPRT) control cells within 5 days of transfection (Suppl. Fig. 4).
This suggested a speciﬁc effect, resulting from loss-of-function of
Rasip1 in MS1 cells.
To examine whether reduction of Rasip1 levels might have a
functional impact on MS1 cell behavior, we carried out both in vitro
tube-formation and wound-healing assays. These assays allowed
evaluation of the effect of Rasip1 knockdown on endothelial
angiogenesis and cell motility, respectively. Strikingly, siRasip1-
treated MS1 cells, in which Rasip1 transcript levels were signiﬁcantly
reduced (Fig. 4A), almost completely lost the ability to form plexus-
like vascular structures when cultured onMatrigel (Figs. 4B, D–F). This
observation supports the notion that Rasip1 is required for endothelial
function. To evaluate the effect, we quantiﬁed the number of branch
points created by the coalescence of ECs into cords/tubes, and found
that these were reduced by over 85%.
In addition, ablation of Rasip1 function in MS1 cells also
dramatically decreased EC migration ability. Using an in vitro scratch
assay, the ‘healing rate’ of a scratch ‘wound’, across amonolayer of ECs,
was signiﬁcantly reduced. While unmanipulated or siHPRT trans-
fected cells were able to heal the wound following overnight
Fig. 4. Rasip1 ablation in MS1 cells by transient siRNA transfection hinders endothelial tube formation and motility. (A) Semi-quantitative RT-PCR (30 cycles) shows the knockdown
of Rasip1 at the mRNA level. HPRT control knockdown is also shown. (B, D–F) siRasip1 treated MS1 cells fail to form “tubes” when plated on Matrigel. (B) Quantiﬁcation shows that
formation of linear structures (tubes or cords) as measured by counting branching points in the vascular plexus, is decreased by approximately 85%. (C, D′–F′, D″–F″) Knockdown of
Rasip1 inhibits endothelial cell migration. siRasip1-treated cells show slow healing rate in “scratch assay”. While untreated cells migrate quickly into the cell-free area (D′, D″),
siRasip1-treated cells migrate less than half the distance during the same time period (F′, F″). (C) Quantiﬁcation of endothelial migration in the scratch assay was determined by
difference in relative diameter of scratch, before and after healing (D′–F′, compared to D″–F″), measured in μm on Y axis (as shown).
275K. Xu et al. / Developmental Biology 329 (2009) 269–279incubation (i.e. ﬁll in the ∼600 μm cell-free wound area), siRasip1
transfected cells migrated only about 50% the distance over that same
timeframe (Figs. 4D′–F′, D″–F″). In sum, control cells could migrate
approximately 300 μm on each side to ﬁll in the gap, while siRasip1
treated cells migrated less than 150 μm. It is unlikely that this effect is
indirect, as a result of decreased cell proliferation, since the timeframe
of the healing study is too short to allow signiﬁcant proliferation
within the gap (wound-healing assay is carried out overnight, and
MS1 doubling time is approximately 24 h). In support, we detect no
signiﬁcant difference in endothelial proliferation by Ki67 staining in
siRasip1-treated cells, following a short siRNA treatment of 3 days
(Suppl. Fig. 5). (Of note, we do detect a mild effect on EC proliferation
over a longer treatment period of 6 days). Together, these results
indicate that Rasip1 function is required in cultured ECs, for both
angiogenic coalescence and cell motility, and is therefore likely to play
important roles in blood vessel development.
Rasip1 is required for embryonic blood vessel formation
Bioinformatic comparison of Rasip1 sequences revealed that it was
highly conserved across many different species, from human to lower
vertebrates, including frog. The DILute domain of Rasip1, for instance,
displayed almost 85% identity at the amino acid level between mouse
and X. tropicalis (Suppl. Fig. 6). This high level of similarity suggested
Rasip1might also be expressed in the vessels of other species, such asfrog, and might play a conserved role in vessel formation. Thus, to
assay Rasip1 function during embryonic vessel formation in vivo, we
examined its expression and function in X. tropicalis embryos. This
tractable model system provided us with an avenue for in vivo assays.
RT-PCR was used to amplify a fragment containing approximately
1900 bp of the Rasip1 coding region from X. tropicalis cDNA. Using
this construct, we generated Dig-labeled probe for in situ hybridiza-
tion and compared Rasip1 expression to known vascular markers
(Figs. 5A–H). We note that vegfr2 (Fig. 5A), erg (Fig. 5B), VE-cadherin
(Fig. 5C), and msr (Fig. 5D) expression patterns outline the early
vasculature in X. tropicalis, during both vasculogenesis and angiogen-
esis, as previously described in Xenopus laevis (Baltzinger et al., 1999;
Devic et al.,1996). Similarly, we found that Xenopus Rasip1 is expressed
in the developing vasculature throughout development, including
early expression in emerging angioblasts (stage 25) and during vessel
coalescence (Figs. 5E–G). In addition, Rasip1 is expressed strongly
during angiogenesis, in sprouting ISVs (Fig. 5G), and remains
expressed after initiation of heart beat (st.34) and blood circulation
(Fig. 5H).
To determine if Rasip1 function is required for vessel development
in vivo, we targeted the sequence in X. tropicalis embryos with
antisense Rasip1 morpholino oligos (Rasip1-MO) designed to inhibit
splicing of Rasip1 transcripts (Suppl. Fig. 7). RT-PCR analysis with
primers spanning the exon–intron boundary conﬁrmed that Rasip1
splicing, and hence expression of mature transcripts, was effectively
Fig. 5. Rasip1 knockdown in frog embryos results in failure of blood vessel formation. Expression of Xenopus tropicalis Rasip1 transcripts in frog embryos by in situ hybridization
marks the developing embryonic blood vessels (in all panels anterior is to the left). (A–D) Vascular markers reveal the embryonic vasculature at stages indicated, including angioblasts
(white arrowheads in A, B) and developing blood vessels, such as the posterior cardinal vein (black arrow, B–D). (A) vegfr2; (B) erg, vascular ETS factor; (C) ve-cad, vascular endothelial
cadherin; D)msr, vascular G-protein coupled receptor. (E–H) Rasip1 initially marks scattered angioblasts (E, st.25), but progressively marks aggregating ﬂank vessels (F, st.28). (G) As
vessels form, Rasip1 marks all embryonic frog vessels examined, including the ﬂank plexus (red arrow), endocardium (red arrowhead), cardinal veins (black arrow) and ISVs (black
arrowheads). (H) Expression of Rasip1 declines slightly in vessels as they mature (including data not shown). (I) Schematic of microinjection of Rasip1 morpholino injections into
blastomeres of early cleavage stage embryo. (J) Semi-quantitative RT-PCR shows the knockdown of Rasip1 transcript expression in radially injected embryos (24 cycles). (K–N)msr in
situ hybridization of injected embryo, outlining vasculature on either uninjected (K, M) or injected (L, N) sides. (K, M) Uninjected side of embryo displays major blood vessels,
including the prominent cardinal vein (black arrow) and ISVs. (M) Higher magniﬁcation of embryo in panel K, showing ISVs sprouting from the cardinal vein on the uninjected side
(black arrowheads). (L, N) MO-injected side of embryos shows a severe reduction in vascular structures, including absence of cardinal vein (yellow arrow) and reduced plexus vessels
(thick yellow arrow). (N) Higher magniﬁcation of embryo in panel L, showing complete absence of both ISVs (white arrowhead) and cardinal vein (yellow arrow). Note that faint
outline of ISVs in panel N results from ISVs from uninjected side appearing through the dorsal ﬁn tissue (white arrowhead). (O) Transverse sections through injected embryos show
that cardinal veins and ISVs are lost on the injected side (arrowheads) but not the uninjected side (arrows). (P) Quantiﬁcation of observations in K–O. Total number of ISVs and ﬂank
plexus branch points were counted from the injected versus uninjected sides of MO-injected embryos. Y axis for ISVs is to left; Y axis for ﬂank branch points is to right. The scale bars
represent 250 μm (A–H), 100 μm (K, L), and 50 μm (M–O), respectively.
Table 1
Rasip1 is required for proper blood vessel formation.
msr
(st.20–21)
ﬂk1
(st.25–27)
erg
(st.33–35)
VE-cadherin
(st.33–35)
msr
(st.35–37)
Uninjected 1/21 1/17 0/13 0/16 0/25
16 ng Rasip1-MO 1/19 10/14 12/15 11/15 4/5
Listed in the table are the numbers of embryos with absent/severely reduced
angioblasts (st.20–27) or posterior cardinal vein (st.33–37) observed on injected side
of embryo (x), out of the total number assayed (y): x/y. Controls include uninjected
embryos (top row) and uninjected side of injected embryos (data not tabulated).
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5J). To speciﬁcally examine the effect of Rasip1 knockdown on
embryonic blood vessel development, we injected the Rasip1-MO
(16 ng), into one side of the embryos at the 2-cell stage and then
assayed them by in situ hybridization at stage 32 with the endothelial
marker msr (Figs. 5K–O).
We found that blood vessel development was severely inhibited in
Rasip1 MO-injected embryos as detected by msr staining (compare
Figs. 5K to L). Most strikingly, we found that the posterior cardinal
vein failed to form on the injected side in 77% of injections that were
assayed at later stages of development (st.33–35) (Suppl. Fig. 8). In
addition, we noted a signiﬁcant reduction in both the number of ECs,
as marked bymsr, along the ﬂank of the embryo, and the organization
of these cells into the vitelline plexus (reduction of average branch
points from 23 to 4) (Figs. 5L, P). The uninjected side, in contrast,
remained unaffected and displayed normal vascular structures,
including a normal posterior cardinal vein (Figs. 5K, M). We alsoobserved that sprouting ISVs failed to appear, which was not
surprising as they originate from the posterior cardinal vein (Figs.
5N, P). Sectioning of injected embryos revealed the distinct absence of
the posterior cardinal vein and ISVs on the injected side (Fig. 5O).
Quantiﬁcation of these observations showed that the cardinal vein
and ISVs were lost over 90% of the time, while the plexus EC branching
277K. Xu et al. / Developmental Biology 329 (2009) 269–279was reduced by over 80%. We detect these effects on the vasculature
using the endothelial markers msr, vegfr2, erg or VE-cadherin (Suppl.
Fig. 8). Interestingly, assays at earlier stages of development (st.20–
21), usingmsr, do not reveal reduction in the number of angioblasts at
the location of the posterior cardinal vein, indicating that vasculogen-
esis, not speciﬁcation, is affected in MO-injected embryos (Table 1).
These experiments provide evidence that Rasip1 is required in vivo for
proper vessel development.
Discussion
This report provides the ﬁrst evidence that Rasip1 is both
expressed and required in the endothelium of the embryonic
vasculature. We show that Rasip1 is speciﬁcally expressed in the
endothelium of the developing blood vessels of both mouse and frog
embryos. Additionally, we demonstrate that this expression initiates
early, in angioblasts prior to their aggregation into vessels, and
continues in established vessels, which grow and remodel via
angiogenesis. We also demonstrate that Rasip1 is fundamentally
required in ECs, both in vitro and in vivo. Knocking down Rasip1 in
cultured ECs inhibits their migration and coalescence into vessel-like
structures, while knocking down Rasip1 in amphibian embryos results
in failure of vessel development. These ﬁndings establish Rasip1 as a
novel and robust marker of embryonic ECs, throughout their
speciﬁcation and differentiation, and as a likely important regulator
of vascular development.
Rasip1 is a novel endothelial marker
Few vascular genes have proven useful as speciﬁc markers of the
endothelium. VEGFR2, PECAM, Tie2 and VE-cadherin are the most
frequently used markers available to date, in that they are highly
enriched in ECs and are often used as speciﬁc markers. However, they
are not completely endothelial speciﬁc, as they are often transiently
expressed in other tissues, at some point during development. For
instance, VEGFR2 is also detected in hematopoietic cells (Yamaguchi
et al., 1993), PECAM is also in macrophages (Lee, 1991), Tie2 is found
in mesenchymal cells of heart outﬂow tracts (Kisanuki et al., 2001),
VE-cadherin is also expressed in liver hematopoietic stem cells (Kim
et al., 2005) and both VEGFR2 and PECAM are also found in lymphatic
vessels (Enholm et al., 2001). In addition, most other commonly used
endothelial markers such as Dll4, Egl7, ephrin-B2, EphB4, Jagged1,
Notch1 and many more, are widely expressed in a number of other
organs and tissues (Conway et al., 2001; Eichmann et al., 2005; Torres-
Vazquez et al., 2003).
This report adds Rasip1 to the short list of useful endothelial-
enriched sequences, which can be used to study the developing
cardiovascular system. Like VEGFR2, Rasip1 transcript levels are highly
enriched in embryonic ECs. This is in contrast to PECAM and Tie2
whose transcript levels are lower, and thus difﬁcult to visualize by in
situ hybridization. While we have assayed commercially available
antibodies to RASIP1 protein, both in vitro and in vivo, none have
proven useful for either immunoﬂuoresence or immunohistochem-
istry. Until effective antibody reagents become available, assays for
Rasip1 transcripts will be useful for studies ranging from examination
of early angioblast speciﬁcation to vasculogenesis and angiogenic
vessel formation. Given its expression conservation across species, in
both frog and mouse, it will very likely be more widely applicable to
vascular studies in other species as well.
Rasip1 is essential for endothelial cell function
Knockdown of Rasip1 levels in cultured ECs reveals a critical role
for Rasip1 in basic cellular functions, such as cell motility and
angiogenesis. When Rasip1 function is reduced, both these basic
endothelial behaviors are severely abrogated. siRasip1-treated cells,but not siHPRT-treated cells, display a reduction in their propensity to
aggregate and form cords or vessels, in a matrigel angiogenesis assay.
In addition, whereas untreated or control siRNA-treated ECs will
normally migrate actively across tissue culture-treated plastic in vitro,
such as in a ‘wound-healing’ assay, cells lacking Rasip1 function fail to
migrate. We propose that this reﬂects a direct effect on EC motility,
since we detect no decrease in the rate of endothelial proliferation in
siRasip1-treated cells when we use Ki67 to assay dividing cells.
Given that these basic cellular behaviors are likely to comprise the
foundations of vessel formation, we predicted that endothelial cells in
emerging blood vessels would also require Rasip1 function. Indeed,
reduction of Rasip1 in vivo leads to a dramatic failure of embryonic
vessel formation. Using a MO-based approach, we knocked down
endogenous expression of Rasip1 in X. tropicalis embryos, which led to
a clear failure of the posterior cardinal vein and associated ISVs to
form. These results demonstrate that Rasip1 is required for the proper
formation of vascular structures that develop via both vasculogenesis
(posterior cardinal vein) and angiogenesis (ISVs). Interestingly,
vessels of the ﬂanking vitelline plexus, within the lateral plate
mesoderm, while disorganized when Rasip1 function is reduced,
were not completely abrogated. The basis for the difference in the
response of these different vascular beds to the absence of Rasip1 is
unclear. However, it has been proposed that inherently different
populations of hematopoietic, and perhaps endothelial, cells arise
within these different embryonic regions (Kau and Turpen, 1983;
Maeno et al., 1985). It is possible that they may represent ‘primitive’
(ventral/ﬂank) versus ‘deﬁnitive’ (dorsal lateral plate/somite) ECs,
and that these two populations have a differential requirement for
Rasip1 function.
Rasip1 is not required for angioblast speciﬁcation
Signiﬁcantly, despite disruption of vessels when Rasip1 function is
knocked down in frog embryos, angioblasts still emerge within the
mesoderm. This ﬁnding indicates that Rasip1 plays a role sometime
after initial angioblast speciﬁcation. This observation is supported by
the timing of Rasip1 expression initiation during vessel development
in frogs, as angioblast speciﬁcation is conveniently separated in time
from the process of vessel formation via vasculogenesis. In frogs,
angioblasts are speciﬁed within the mesoderm of late neurula stage
embryos (st.18–22), many hours prior to vessel formation that occurs
at the late tailbud stage (st.30–32). We ﬁnd that Rasip1 expression in
frogs initiates later (st.22) than VEGFR2 (st.18) (Cleaver et al., 1997),
thus displaying a marked delay and appearing distinctly later than the
earliest known angioblast markers. In addition, when Rasip1 function
is knocked down usingMOs, we observe that early angioblasts emerge
relatively normally as assayed by msr expression at st.20–21. We
therefore suggest that Rasip1 is likely to function in angioblasts and
ECs following their initial speciﬁcation, possibly during their migra-
tion, cord formation or tubulogenesis.
In contrast, we observe that Rasip1 expression in mouse appears to
be initiated remarkably early, around the same time that VEGFR2 and
other vascular markers begin transcription within the earliest
endothelial precursors of the yolk sac. This is not surprising since
most murine endothelial markers initiate almost simultaneously
during a relatively short timeframe, making it difﬁcult to establish
the order of vascular gene onset (Drake and Fleming, 2000). It will
therefore be necessary to carry out more detailed expression analyses
of vascular markers, or functional epistases experiments, during this
initial phase of vasculogenesis to determinewhen Rasip1may exert its
function and to place it within potential regulatory genetic cascades.
Summary
Data presented here supports a requirement for Rasip1 function
within developing ECs during blood vessel formation. Knockdown of
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and ISVs to develop and in disorganization of the vitelline plexus.
However, at this point, the cellular and molecular mechanisms that
prevent the proper formation of these vessels remain unclear. At the
cellular level, it is likely that the observed vascular defects are a result
of either a reduction of angioblast survival, or a failure of cord
formation via vasculogenesis or vascular tube formation, with
subsequent cell death or dedifferentiation. At the molecular level, it
is not yet clear how, when and whether Rasip1 modulates Ras
downstream of VEGF signaling, or whether it impacts alternative
pathways. Studies are currently underway to clarify these molecular
relationships during vascular development.
Together, our studies demonstrate the critical role of the Ras effector
Rasip1 for proper vessel formation and normal endothelial cell
behavior. In addition, we identify Rasip1 as a novel tool for studies of
embryonic vessel development. In vitro experiments demonstrate that
Rasip1 is required for EC migration and coalescence of angioblasts into
vessels, while in vivo experiments show that it is required for formation
of blood vessels in frog embryos. Due to its conservation, we predict
that Rasip1will also be required for proper formation of the vasculature
in other species, including mammals. Further studies of Rasip1 will
open novel and exciting questions regarding the role of intracellular
signalingmolecules in vascular development, includingmembers of the
Ras family, both areas which to date have been relatively unexplored.
Given the central importance of blood vessels during many diseases,
such as cancer and tumor angiogenesis, we propose that further
understanding of the mechanism and impact of Ras and Rasip1
signaling in ECs will prove to be of great clinical relevance.
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